Gloria Esteso

Gloria Esteso


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
EMEduardo Moreo
Eduardo Moreo
AJAitor Jarit-Cabanillas
Aitor Jarit-Cabanillas
IRIñaki Robles-Vera
Iñaki Robles-Vera
SUSantiago Uranga
Santiago Uranga
CGClaudia Guerrero
Claudia Guerrero
NANacho Aguiló
Nacho Aguiló
Intravesical administration of Bacillus Calmette-Guérin (BCG) was one of the first FDA-approved immunotherapies and remains a standard treatment for bladder cancer. Previous studies have demonstrated that intravenous (IV) administration of BCG is well-tolerated and effective in preventing tuberculosis infection in animals. Here, we examine IV BCG in several preclinical lung tumor models. Our findings demonstrate that BCG inoculation reduced tumor growth and prolonged mouse survival in models of lung melanoma metastasis and orthotopic lung adenocarcinoma. Moreover, IV BCG treatment was well-tolerated with no apparent signs of acute toxicity. Mechanistically, IV BCG induced tumor-specific CD8+ T cell responses, which were dependent on type 1 conventional dendritic cells, as well as NK cell-mediated immunity. Lastly, we also show that IV BCG has an additive effect on anti-PD-L1 checkpoint inhibitor treatment in mouse lung tumors that are otherwise resistant to anti-PD-L1 as monotherapy. Overall, our study demonstrates the potential of systemic IV BCG administration in the treatment of lung tumors, highlighting its ability to enhance immune responses and augment immune checkpoint blockade efficacy.

30 June 2011 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
MJMette Jacobsen
Mette Jacobsen
SCSusanna Cirera
Susanna Cirera
DJDavid Joller
David Joller
GEGloria Esteso
Gloria Esteso
SKSteffen S Kracht
Steffen S Kracht
CJClaus B Jørgensen
Claus B Jørgensen
Background: Enterotoxigenic Escherichia coli (ETEC) that express the F4ab and F4ac fimbriae is a major contributor to diarrhoea outbreaks in the pig breeding industry, infecting both newborn and weaned piglets. Some pigs are resistant to this infection, and susceptibility is inherited as a simple dominant Mendelian trait. Indentifying the genetics behind this trait will greatly benefit pig welfare as well as the pig breeding industry by providing an opportunity to select against genetically susceptible animals, thereby reducing the number of diarrhoea outbreaks. The trait has recently been mapped by haplotype sharing to a 2.5 Mb region on pig chromosome 13, a region containing 18 annotated genes. Findings: The coding regions of five candidate genes for susceptibility to ETEC F4ab/ac infection (TFRC, ACK1, MUC20, MUC4 and KIAA0226), all located in the 2.5 Mb region, were investigated for the presence of possible causative mutations. A total of 34 polymorphisms were identified in either coding regions or their flanking introns. The genotyping data for two of those were found to perfectly match the genotypes at the ETEC F4ab/ac locus, a G to C polymorphism in intron 11 of TFRC and a C to T silent polymorphism in exon 22 of KIAA0226. Transcriptional profiles of the five genes were investigated in a porcine tissue panel including various intestinal tissues. All five genes were expressed in intestinal tissues at different levels but none of the genes were found differentially expressed between ETEC F4ab/ac resistant and ETEC F4ab/ac susceptible animals in any of the tested tissues. Conclusions: None of the identified polymorphisms are obvious causative mutations for ETEC F4ab/ac susceptibility, as they have no impact on the level of the overall mRNA expression nor predicted to influence the composition of the amino acids composition. However, we cannot exclude that the five tested genes are bona fide candidate genes for susceptibility to ETEC F4ab/ac infection since the identified polymorphism might affect the translational apparatus, alternative splice forms may exist and post translational mechanisms might contribute to disease susceptibility.

4 July 2019 in Cancers
Verified
Journal Article
Open access
PDF file
OAOmodele Ashiru
Omodele Ashiru
GEGloria Esteso
Gloria Esteso
EGEva M. García-Cuesta
Eva M. García-Cuesta
ECEva Castellano
Eva Castellano
CSCelia Samba
Celia Samba
MVMar Vales-Gomez
Mar Vales-Gomez
Background: Intra-vesical instillation of Bacille Calmette–Guérin (BCG), an attenuated strain of Mycobacterium bovis, is an effective therapy for high-grade non-muscle invasive bladder cancer (NMIBC), which provokes a local immune response resulting in 70% of patients free of relapse after three years. Because non-responder patients usually have a bad prognosis, the early identification of treatment failure is crucial. We hypothesized that, if an effective immune response was taking place in the bladder, soluble factors would be released to the urine many days after BCG instillations. Methods: An extensive panel of cytokines and chemokines released into the urine seven days after every BCG instillation was screened in a cohort of NMIBC patients over three years. Results: The determinations of the urinary concentrations of cytokines, chemokines, and creatinine showed that increasing concentrations of C-X-C motif chemokine 10 (CXCL10) also known as interferon-inducible protein 10 (IP10) could be detected during the six-week induction cycle of BCG-treated patients released into the urine by CD14+ cells. In vitro, CXCL10 facilitated the recruitment of effector immune cells after the BCG-mediated upregulation of CXCR3 in both T- and natural killer (NK)-cells. Conclusions: The high concentrations of chemokine detected one week after the encounter with mycobacteria suggest that the CXCL10 axis might be related to the intensity of the immune anti-tumor response.

18 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
PMPedro Martínez-Fleta
Pedro Martínez-Fleta
AAArantzazu Alfranca
Arantzazu Alfranca
IGIsidoro González-Álvaro
Isidoro González-Álvaro
JCJose M. Casasnovas
Jose M. Casasnovas
DFDaniel Fernández-Soto
Daniel Fernández-Soto
MVMar Vales-Gomez
Mar Vales-Gomez
Currently, there is a need for reliable tests that allow identification of individuals that have been infected with SARS-CoV-2 even if the infection was asymptomatic. To date, the vast majority of the serological tests for SARS-CoV-2 specific antibodies are based on serum detection of antibodies to either the viral spike glycoprotein (the major target for neutralising antibodies) or the viral nucleocapsid protein that are known to be highly immunogenic in other coronaviruses. Conceivably, exposure of antigens released from infected cells could stimulate antibody responses that might correlate with tissue damage and, hence, they may have some value as a prognostic indicator. We addressed whether other non-structural viral proteins, not incorporated into the infectious viral particle, specifically the viral cysteine-like protease, might also be potent immunogens. Using ELISA tests, coating several SARS-CoV-2 proteins produced in vitro, we describe that COVID-19 patients make high titre IgG, IgM and IgA antibody responses to the Cys-like protease from SARS-CoV-2, also known as 3CLpro or Mpro, and it can be used to identify individuals with positive serology against the coronavirus. Higher antibody titres in these assays associated with more severe disease and no cross-reactive antibodies against prior betacoronavirus were found. Remarkably, IgG antibodies specific for Mpro and other SARS-CoV-2 antigens can also be detected in saliva. In conclusion, Mpro is a potent antigen in infected patients that can be used in serological tests and its detection in saliva could be the basis for a rapid, non-invasive test for COVID-19 seropositivity.

1 April 2014 in European Urology Supplements
Verified
Journal Article
Closed access
EGEva M. García-Cuesta
Eva M. García-Cuesta
GEGloria Esteso
Gloria Esteso
Mario Alvarez-MaestroMario Alvarez-Maestro
Mario Alvarez-Maestro
SLS. Lopez-Cobo
S. Lopez-Cobo
ALA. Linares
A. Linares
MVMar Vales-Gomez
Mar Vales-Gomez

31 October 2022 in Research Square
Verified
Preprint
Open access
PDF file
NANacho Aguilo
Nacho Aguilo
EMEduardo Moreo
Eduardo Moreo
IRIñaqui Robles
Iñaqui Robles
CGClaudia Guerrero
Claudia Guerrero
AJAitor Jarit
Aitor Jarit
David SanchoDavid Sancho
David Sancho
Intravesical administration of BCG was the first immunotherapy approved by the FDA and it is still nowadays the treatment of choice for a subset of non-muscle invasive bladder cancer patients. Considering this precedent and the strong capabilities of BCG to trigger cellular responses, we hypothesized that systemic administration of BCG by the intravenous route (IV BCG), a vaccination strategy that has been found well-tolerated, highly immunogenic and effective at preventing tuberculosis infection in non-human primates, could result effective against lung tumors. Our data revealed that IV BCG, administered in a therapeutic scenario, slowed tumor growth and extended mouse survival in models of B16-F10 lung metastasis and in an orthotopic LLC lung cancer model, by enhancing both antitumoral innate and adaptive immune responses. IV BCG administration induced tumor-specific CD8+ T cell responses with enhanced cytotoxic function, in a process dependent on conventional type 1 Dendritic Cells (cDC1s). In addition, we found that BCG strongly activated both human and mouse NK cells. Remarkably, NK cell depletion prevented BCG-induced cDC1 recruitment to the tumor-bearing lung and reduced cDC1 upload with tumor-derived antigens, as well as the subsequent induction of tumor-specific CD8+ T cell responses and tumor control. Of note, IV BCG strongly synergized with the immune checkpoint inhibitor (ICI) anti-PD-L1 in lung tumors which were otherwise resistant to immune checkpoint blockade given as monotherapy, suggesting the IV BCG could represent a promising ICI-resensitizing cancer immunotherapy.